Genome-wide Analysis of Simultaneous GATA1/2, RUNX1, FLI1, and SCL Binding in Megakaryocytes Identifies Hematopoietic Regulators

Citation for published version:
https://doi.org/10.1016/j.devcel.2011.04.008

Digital Object Identifier (DOI):
10.1016/j.devcel.2011.04.008

Link:
Link to publication record in Edinburgh Research Explorer

Published In:
Developmental Cell

Publisher Rights Statement:
Copyright © 2011 ELL & Excerpta Medica.
This document may be redistributed and reused, subject to certain conditions.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Genome-wide Analysis of Simultaneous GATA1/2, RUNX1, FLI1, and SCL Binding in Megakaryocytes Identifies Hematopoietic Regulators

Marloes R. Tijssen,1,2,4 Ana Cvejic,2,3,4 Anagha Joshi,1 Rebecca L. Hannah,1 Rita Ferreira,1 Ariel Forrai,1 Dana C. Bellissimo,2,3 S. Helen Oram,1 Peter A. Smethurst,2 Nicola K. Wilson,1 Xiaonan Wang,1 Katrin Ottersbach,1 Derek L. Stemple,3 Anthony R. Green,1 Willem H. Ouwehand,2,3,* and Berthold Göttgens1, *

1Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, UK
2Department of Haematology, NHS Blood and Transplant Centre, University of Cambridge, Cambridge CB2 0PT, UK
3Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
4These authors contributed equally to this work
*Correspondence: who1000@cam.ac.uk (W.H.O.), bg200@cam.ac.uk (B.G.)

DOI 10.1016/j.devcel.2011.04.008

SUMMARY

Hematopoietic differentiation critically depends on combinations of transcriptional regulators controlling the development of individual lineages. Here, we report the genome-wide binding sites for the five key hematopoietic transcription factors—GATA1, GATA2, RUNX1, FLI1, and TAL1/SCL—in primary human megakaryocytes. Statistical analysis of the 17,263 regions bound by at least one factor demonstrated that simultaneous binding by all five factors was the most enriched pattern and often occurred near known hematopoietic regulators. Eight genes not previously appreciated to function in hematopoiesis that were bound by all five factors were shown to be essential for thrombocyte and/or erythroid development in zebrafish. Moreover, one of these genes encoding the PDZK1IP1 protein shared transcriptional enhancer elements with the blood stem cell regulator TAL1/SCL. Multifactor ChIP-Seq analysis in primary human cells coupled with a high-throughput in vivo perturbation screen therefore offers a powerful strategy to identify essential regulators of complex mammalian differentiation processes.

INTRODUCTION

Complex gene-regulatory networks control all metazoan development (Davidson, 2001). Transcription factors (TFs) and the cis-regulatory sequences to which they bind form the building blocks of these gene-regulatory networks. Connectivity in these networks has historically been determined using individual gene-based assays or inferred from expression profiling. However, gene by gene characterization of regulatory elements is slow and inference of regulatory relationships based on variations in gene expression alone cannot readily differentiate between direct and indirect interactions. New genome-wide technologies permit potentially rapid access to all regions bound by a given factor. However, binding of a factor does not necessarily equate with direct regulation of nearby genes. New strategies are therefore required to identify the subsets of binding events that are central to regulatory network function.

Hematopoiesis has long served as a model process for studying stem cells (Orkin and Zon, 2008). One of the earliest branch points during hematopoietic differentiation is the specification of the megakaryocyte (MK)/erythroid progenitor (MEP) (Adolfsson et al., 2005). Subsequent formation of immature MKs leads to the production of large numbers of anucleate platelets. As the second most abundant cell in the blood, their primary role is to maintain hemostasis and instigate wound healing on vascular damage.

Being derived from a common precursor, the MK and erythrocyte lineages share a number of TFs critical for their development, including GATA1, FOG1, SCL, and GFI1b. Other factors, like EKLF (erythroid) and GABPα, FLI1, and RUNX1 (megakaryocytic) have been implicated in the bifurcation of these lineages. Analysis of cell-type specific regulatory elements is consistent with the notion that combinations of these TFs constitute lineage-specific regulatory codes. For example, sites for GATA1 and SCL are found in several erythroid specific enhancers (Anderson et al., 1998; Wadman et al., 1997) and several enhancers active in MKs contain GATA and ETS binding sites (Minami et al., 1998; Yamaguchi et al., 1998).

We have recently reported genome-wide combinatorial interactions for ten key regulators of hematopoietic stem/progenitor cells in the multipotent mouse hematopoietic progenitor cell line 7 (HPC-7) (Wilson et al., 2010a), which revealed combinatorial interactions between a heptad of TFs (Scl, Lyl1, Lmo2, Gata2, Runx1, Erg, Flt1). Subsequent in vivo validation confirmed a previously unrecognized synergism between the three central regulators of blood stem cell development Scl, Gata2, and Runx1. Another elegant study examined the dynamic binding and long-distance regulation by multi-TF complexes during erythroid maturation using a mouse erythroleukemia cell line model (Soler et al., 2010). Furthermore, recent studies have extended genome-wide analysis of key hematopoietic transcription factors to human leukemia cell lines (Fujii et al., 2009; Pencovich et al., 2011). However, all the above studies were performed in transformed cell lines. Any findings therefore come
with the many caveats associated with the unphysiological nature of immortalized cells. Here we report the genome-wide binding of five key hematopoietic regulators in primary human MKs. Knockdown in zebrafish of eight genes, regulated by all five TFs and with no known function in hematopoiesis, showed all to be essential for thrombocyte and/or erythroid development, suggesting that multifactor chromatin immunoprecipitation sequencing (ChIP-Seq) combined with high-throughput zebrafish screening is a widely applicable strategy to identify regulators of complex mammalian developmental processes.

**RESULTS**

**Genome-Wide Analysis of GATA1, GATA2, RUNX1, FLI1, and SCL Binding in Primary Human Megakaryocytes**

To determine genome-wide TF binding, primary MKs were cultured from cord blood CD34⁺ hematopoietic progenitor cells (HPCs; ≥98% pure) for 10 days in the presence of thrombopoietin and interleukin-1β (Figure 1A). 3.3 million CD34⁺ cells produced a total of 94.7 million primary cells, sufficient for comprehensive genome-wide analysis. After culture, 71%–93% of cells expressed CD41 (Figure 1B) and 20%–56% expressed the more mature marker CD42a (data not shown). Cytospin and modified Wright’s stain demonstrated that most cells were at the megakaryoblast stage, however, some pro-MKs with nuclear separation were also seen (Figure 1B). Greater than 90% of cells tested negative for CD34 expression and few cells expressed markers of other lineages (CD11c, 0.4%–4.1%; CD14, 2.4%–2.7%; CD15, 0.7%–2.3%; CD66a, 0.5%–1%; data not shown).

ChIP-Seq technology was then used to generate genome-scale catalogs of sequences bound by GATA1, GATA2, RUNX1,
FLI1, and SCL in primary human MKs. Before sequencing, ChIP material was validated by quantitative polymerase chain reaction (PCR). We have previously shown that the RUNX1 +23 enhancer is bound by GATA2, RUNX1, FLI1, and SCL in mouse progenitor cells (Wilson et al., 2010a), and the SCL +40 enhancer by GATA1 in erythroid cells (Ogilvy et al., 2007). As shown in Figure 1C, significant binding of the relevant factors to these two regions was also observed in primary human MKs.

The ChIP material was sequenced yielding between 10.3 million and 14.1 million mappable reads for each factor. Visualization of the raw data across the RUNX1 and TAL1 loci reproduced the PCR results with specific enrichment of the RUNX1 +23 and SCL +40 regions (Figures 2A and 2B, respectively). Inspection of several gene loci for MK-affiliated genes showed that (1) the ITGA2B locus (coding for integrin αIIb, the CD41 marker used to determine the purity of the MK cultures) is bound by all five TFs (Figure 2C); (2) GP9 coding for the MK-specific protein GPIX is bound by all but GATA2 (Figure 2D); and (3) GP1BB is bound by all five TFs just like CD41 (Figure 2E).

To comprehensively identify all binding peaks across the genome, we generated a control IgG ChIP sample to permit the use of software tools specifically designed to eliminate artifactual peaks found in both test and control samples, which allowed us to identify 4722 peaks for GATA1, 2475 peaks for GATA2, 7345 peaks for RUNX1, 8688 peaks for FLI1, and 3085 peaks for SCL (Figure 2F). Over 33% of RUNX1 and FLI1 peaks were situated in promoter regions, whereas for GATA1, GATA2, and SCL this did not exceed 14%.

Analysis of Combinatorial Interactions Highlights a Preference for All Five Factors Binding Together

To obtain new insights into combinatorial TF interactions, we next asked whether the frequency of colocalization of specific combinations of TFs on the same target regions might indicate preferential coregulatory activities. To this end, we determined the number of overlapping peaks for all 26 possible combinations involving binding of two or more factors (Figure 3A, left; see Tables S1 and S2 available online for all peak coordinates and candidate target genes). To address statistical significance, we used a lower end estimate of 80,000 regions potentially available for binding (Boyle et al., 2008; McDaniell et al., 2010), determined the expected frequencies for all 26 binding patterns and calculated significance of deviation between observed and expected values (Figure 3A, right). The most underrepresented pattern was binding by GATA1 and FLI1 without any other factor, suggesting that binding by GATA1 and FLI1 in the absence of larger multi-TF-complexes is not favored. Interestingly, seven of eight combinations involving GATA1 and SCL were overrepresented pointing to the importance of this pairing in megakaryopoiesis (Figure 3A). By far the most significant combinatorial pattern was binding of all five factors together suggesting an important role for this complex
in MK transcriptional control. Of note, there was only a minor overlap between the peaks identified here when compared to those from a recently published study where four of the five factors were analyzed in a mouse hematopoietic progenitor cell line (Figure S1), suggesting that cell-type specific binding patterns of sequences bound only by GATA1 and SCL recover a typical SCL/GATA1 composite binding motif (i), the SCL binding E-box motif (ii), and a motif resembling an E-box (iii). All regions bound by GATA1 and SCL plus one or more of the other factors, recovered GATA, ETS, and RUNX consensus sequences (iv, v, and vi, respectively). See also Tables S1 and S2 and Figure S2.

We next used sets of regions with particular TF occupancy patterns for de novo motif discovery, which recovered the expected consensus binding motifs (Figure 3; see Figure S2 for expected consensus motif sequences). For example, analysis of sequences bound only by SCL and GATA1 recovered a typical SCL/GATA1 composite binding motif (Figure 3Bi), also seen in recent ChIP-Seq studies of Scl in erythroid cells (e.g., Kassouf et al., 2010 and Soler et al., 2010) and now recognized as the likely docking site for Scl/Gata complexes. This analysis also recovered the SCL binding E-box motif (Figure 3Bii) as well as a motif resembling an E-box, but not present in current collections of transcription factor consensus binding sites (Figure 3Biii). Analysis of other subsets such as all regions bound by SCL and GATA1 plus one or more of the other three factors recovered additional expected motifs such as GATA, ETS, and RUNX consensus sequences (e.g., Figures 3Biv–3Bvi), thus demonstrating that expected motifs were present in the regions identified by ChIP-Seq analysis.

**Only a Subset of Peak Occupancy Patterns Correlates with Megakaryocyte-Specific Gene Expression**

Having established the potential importance of combinatorial interactions between GATA1, GATA2, RUNX1, FLI1, and SCL, we next investigated the connectivity within the core network formed by these five factors. As shown in Figure 4A, all five TFs are characterized by a positive autoregulatory feedback loop, and in addition contain extensive cross-regulatory links, thus resulting in the formation of a densely connected core circuit. Studies in lower model organisms have suggested that regulatory networks commonly consists of densely connected TF core circuits that control large numbers of tissue-specific effector proteins (enzymes, structural proteins, etc.) (Davidson, 2010; Roy et al., 2010). With occupancy patterns being nonrandomly distributed (Figure 3A), we next investigated the nature of the candidate target genes for all possible 31 occupancy patterns, and therefore mapped TF binding peaks to nearby genes thus generating 31 target gene lists (Table S2). To identify those sets of target genes most likely to be important for the megakaryocyte phenotype, we next performed gene set enrichment analysis (GSEA), which demonstrated that six occupancy patterns were associated with genes highly enriched for MK-specific expression (Figure 4B and Table S3). Of note, four of these six peak occupancy patterns (P1, P2, P3, P5) had also been found to occur much more frequently than expected by chance (see Figure 3A). This convergence between statistical analysis of peak pattern frequency and GSEA analysis of neighboring genes therefore suggests that key aspects of the megakaryocyte transcriptional program can be captured from comprehensive analysis of our data set.

Of note, none of the 31 gene lists showed significant correlation with genes specifically repressed in MKs, thus suggesting that the five-factor core circuit analyzed here largely functions as a positive regulator of MK expression. To further explore this notion, we performed additional ChIP-Seq experiments to generate genome-wide maps indicative of active and repressed chromatin. trimethylation of histone H3 lysine 4 (H3K4me3) was used to map active promoters, histone H3 acetylation (H3ac) for active promoters as well as more distal elements, and trimethylation of histone H3 lysine 27 (H3K27me3) as a mark for repressed chromatin. All three data sets displayed the expected patterns of enrichment (Figure S3A). We therefore proceeded to categorize all human promoters into three categories (inactive, bivalent and active) based on their pattern of histone modification (Figure S3B). As expected, when gene expression in the three categories was examined, the highest level of expression was found in the category of “active” promoters (Figure S3C). Moreover, the fraction of promoters bound by the five transcription factors was lowest for the inactive promoters, at an intermediate level for bivalent promoters and highest for the active promoters (Figure S3D). Genome-wide analysis of chromatin status was therefore consistent with the notion that the core TF circuit defined here is predominantly involved in positive regulation of gene expression. With analysis of combinatorial binding patterns, gene set enrichment and chromatin analysis all converging on a consistent role for the GATA1/GATA2/RUNX1/FLI1/SCL core circuit within
wider MK transcriptional programs, we next developed a regulatory network model (Lin et al., 2010) illustrating the connectivity of all genes controlled by TF peaks correlating with MK-specific expression (e.g., the gene sets corresponding to patterns P1 to P6 from Figure 4B). As illustrated in Figure 4C, target genes controlled by the six different types of peaks are largely nonoverlapping. This analysis therefore suggests that control of MK effector genes mainly occurs via a single regulatory element whereby several distinct combinations of GATA1/GATA2/RUNX1/FLI1/SCL can be involved in contributing to MK-specific expression.
expression. Taken together, comprehensive bioinformatic analysis has allowed us to generate a regulatory network model for megakaryocyte-specific expression with a densely connected core circuit controlling several hundred effector genes through a relatively shallow hierarchy, a network architecture recently predicted to be common for tissue-specific gene expression programs (Davidson, 2010). It is important to note, however, that not unexpectedly, the current five-factor network model does not capture MK-specific expression in its entirety. Of the top 200 megakaryocyte-specific genes, 67 form part of the current network model, thus suggesting that alternative TF combinations mediating MK-specific expression remain to be discovered.

**In Vivo Validation of Candidate Target Genes in Zebrafish Identifies Eight Hematopoietic Regulators**

With all five factors binding together being the most significant combinational pattern in our data set (Figure 3A) and the most highly enriched for MK-specific genes (Figure 4B and Table S3), we hypothesized that concurrent binding by these five factors represented an important control mechanism for hematopoietic development. To explore this hypothesis further, we used the genomic regions enrichment of annotations tool (GREAT) (McLean et al., 2010), which defines genomic neighborhoods for TF-bound peaks by attaching weights to flanking genes based on their distance to the peak. Weighted gene lists are then used to identify overrepresented biological functions. GREAT analysis for the 144 regions bound by all five TFs showed strong enrichment for a number of phenotypes, all of which were hematopoietic and included decreased platelet count (Table 1). Taken together therefore, concurrent binding of GATA1, GATA2, RUNX1, FLI1, and SCL highlights a set of genes highly enriched for known (and potentially unidentified) regulators of hematopoiesis in general and of megakaryopoiesis more specifically.

To further explore the biological significance of the subset of genes bound by all five TFs, we performed functional studies using zebrafish as a model for high-throughput in vivo validation. Mapping peaks to genes identified 151 candidate target genes for the 144 regions bound by all five TFs of which 24 (16%) have a role in transcriptional control and 28 (19%) are involved in signal transduction (Table S4). Fifty-seven of the 151 genes were (1) expressed in MKs based on a recent compendium of gene expression profiles in primary human hematopoietic cell types (Watkins et al., 2009) and (2) displayed increased expression in a recently published MK differentiation time series data set (Fuhrken et al., 2008). Eighteen of these 57 genes had known hematopoietic functions, and of the remaining 39 genes, zebrafish orthologs could be readily identified for 37 genes. Morpholino antisense oligonucleotides (MOs) were designed against nine candidate genes, we examined

### Table 1. GREAT Analysis Shows Highly Significant Overrepresentation of Hematopoietic Phenotypes and MK Gene Expression Patterns for the Regions Bound by All Five TFs

<table>
<thead>
<tr>
<th>Enriched Term</th>
<th>Raw p value</th>
<th>FDR q value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abnormal hematopoietic system physiology</td>
<td>3.5 E-07</td>
<td>2.0 E-03</td>
</tr>
<tr>
<td>Hematopoietic system phenotype</td>
<td>6.8 E-07</td>
<td>2.0 E-03</td>
</tr>
<tr>
<td>Anemia</td>
<td>1.5 E-06</td>
<td>2.9 E-03</td>
</tr>
<tr>
<td>Abnormal hematopoietic system/development</td>
<td>2.1 E-06</td>
<td>3.0 E-03</td>
</tr>
<tr>
<td>Abnormal hematopoiesis</td>
<td>3.5 E-06</td>
<td>4.0 E-03</td>
</tr>
<tr>
<td>Anemia</td>
<td>4.4 E-06</td>
<td>4.2 E-03</td>
</tr>
<tr>
<td>Abnormal blood cell morphology/development</td>
<td>6.6 E-06</td>
<td>5.5 E-03</td>
</tr>
<tr>
<td>Abnormal immune system morphology</td>
<td>1.2 E-06</td>
<td>8.6 E-03</td>
</tr>
<tr>
<td>Abnormal leukocyte cell number</td>
<td>2.8 E-05</td>
<td>1.5 E-02</td>
</tr>
<tr>
<td>Abnormal leukocyte morphology</td>
<td>4.3 E-05</td>
<td>2.1 E-02</td>
</tr>
<tr>
<td>Abnormal immune system cell morphology</td>
<td>5.1 E-05</td>
<td>2.1 E-02</td>
</tr>
<tr>
<td>Abnormal mononuclear leukocyte cell morphology</td>
<td>7.2 E-05</td>
<td>2.8 E-02</td>
</tr>
<tr>
<td>Decreased platelet cell number</td>
<td>1.6 E-04</td>
<td>4.6 E-02</td>
</tr>
<tr>
<td>MsigDB gene sets perturbation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genes upregulated in AML samples of the FAB class M7</td>
<td>3.1 E-06</td>
<td>2.8 E-03</td>
</tr>
<tr>
<td>Genes essential to the development of megakaryocytes, as expressed in normal cells and essential thrombocythemic cells</td>
<td>1.0 E-05</td>
<td>4.6 E-03</td>
</tr>
</tbody>
</table>

FDR, false discovery rate; GREAT, genomic regions enrichment of annotations tool; TFs, transcription factors.
are highly enriched for previously unknown hematopoietic regulators.

**PDZK1IP1 Shares Transcriptional Enhancer Elements with the Essential Hematopoietic Stem Cell Regulator SCL**

Identification of a hematopoietic function in zebrafish for *pdzk1ip1* was of particular interest because (1) its mammalian ortholog PDZK1IP1 (also known as MAP17) encodes a membrane associated protein shown to modulate the levels of reactive oxygen species (Guijarro et al., 2007) that have recently emerged as important determinants of blood stem cell function (Tothova et al., 2007); (2) PDZK1IP1 is situated immediately 3' of the hematopoietic master regulator SCL (see Figure 6A); (3) this arrangement is conserved between mammals and zebrafish (Gottgens et al., 2002a); and (4) an erythroid enhancer regulating murine *Scl* expression is located 3' of PDZK1IP1 (+40 element; Figure 6A) (Delabesse et al., 2005). We previously argued that this *Scl* 3' enhancer was the cause for close linkage between *Scl* and *Pdzk1ip1* during evolution because major rearrangements would have interfered with SCL expression (Ogilvy et al., 2007). However, the identification of a hematopoietic function for *pdzk1ip1* suggests that the intimate linkage of SCL and PDZK1IP1 might be due to the fact they share regulatory elements to mediate their respective functions in hematopoietic cells. Interestingly, PDZK1IP1 is upregulated during megakaryocyte differentiation from CD34+ HPCs (Fuhrken et al., 2008) and we have previously observed that the *Scl* +19 enhancer targets expression to megakaryocytes (Silberstein et al., 2005).

To investigate the possibility of coregulation, we first determined expression of *Pdzk1ip1* in mouse embryos. As shown in Figure 6B, *Pdzk1ip1* was expressed in the midgestation mouse embryo both in the dorsal aorta (AGM region) and fetal liver in the hematopoietic domains that also express *Scl*. Of note, expression in dorsal aorta endothelium and hematopoietic clusters as well as a subset of fetal liver cells was highly reminiscent of the expression pattern previously seen in transgenic mouse embryos with the +19 enhancer fused to an *Scl*-promoter-lacZ reporter gene (Silberstein et al., 2005).

To examine hematopoietic expression of *Pdzk1ip1* further, we generated embryonic stem cells (ESCs) with a lacZ reporter gene knocked into the ATG start codon of *Pdzk1ip1* (Figures 6C, S5A, S5B, Developmental Cell 20, 597–609, May 17, 2011 ©2011 Elsevier Inc. 603).
Figure 6. PDZK1IP1 Shares Transcriptional Enhancer Elements with the Hematopoietic Master Regulator SCL

(A) ChIP-Seq results (as for Figure 2) across the human SCL/PDZK1IP1 gene locus with the location of the +19 and +40 enhancer elements indicated by arrowheads.

(B) Pdzk1ip1 is expressed in the fetal liver (FL) and dorsal aorta (DA) region of midgestation mouse embryos. Shown are the results from in situ hybridization experiments using transverse sections of day 12.5 mouse embryos with a magnified view of the dorsal aorta on the right hand side.

(C) Targeting of a lacZ reporter gene into the 5'UTR of mouse Pdzk1ip1 in ESCs. The neo selection marker was flanked by loxP sites and removed using Cre-mediated recombination.

(D) Pdzk1ip1 lacZ knockin ESCs express lacZ after differentiation into embryoid bodies. The top section shows day 6 embryoid bodies stained for lacZ using the chromogenic substrate X-Gal with wild-type (wt) cells on the left and Pdzk1ip1 knockin cells (ki) on the right. The bottom part shows flow cytometry analysis using the fluorogenic lacZ substrate FDG with approximately 25% of Pdzk1ip1 knockin cells expressing the lacZ reporter (FDG, x axis; Side Scatter SSC, y axis).

(E) Hematopoietic colony forming activity is confined to Pdzk1ip1 expressing cells in ESC differentiation assays. Pdzk1ip1 expressing cells were purified by flow cytometry and analyzed for colony forming ability. Shown from left to right are colony numbers per 100,000 cells for primitive erythroid (EryP), definitive erythroid (EryD), mixed lineage (Mixed), and macrophage colonies (MP) (mean + SD).

(F) The +19 enhancer drives expression to the fetal liver in transgenic mice when fused to the Pdzk1ip1 promoter. Shown on the left is a representative E12.5 transgenic embryo carrying the Pdzk1ip1 promoter fused to the lacZ reporter gene with no observable staining. Shown on the right is a representative transgenic embryo for the Pdzk1ip1 promoter fused to the +19 enhancer with readily identifiable staining in the fetal liver (arrowhead). See also Figure S5.
and S5B) and then used lacZ expression during ESC differentiation as a surrogate for Pdzk1ip1 expression. ESCs were differentiated into embryoid bodies to produce hematopoietic cells that could be analyzed by flow cytometry and colony assays. At day 6 of differentiation, ~25% of embryoid body cells derived from Pdzk1ip1 knockin (KI) ESCs displayed lacZ staining (Figure 6D) with the vast majority of hematopoietic colony forming activity found in the lacZ expressing cells (Figure 6E). Pdzk1ip1 expression therefore marks hematopoietic cells in both mouse embryos and differentiating ESCs within the known expression domain of Scl.

To investigate whether the regulatory elements previously shown to drive Scl expression can also act on the Pdzk1ip1 promoter, we generated transgenic mouse embryos carrying the Pdzk1ip1 promoter with and without the Scl +19 enhancer fused to a lacZ reporter gene. Of 15 transgenic embryos with the Pdzk1ip1 promoter alone, only two showed expression (in the brain and limb buds, respectively). By contrast, 7 of 15 transgenic embryos for the promoter/enhancer construct showed staining, with five of seven embryos displaying strong staining in the fetal liver (Figure 6F) in a pattern highly reminiscent to what we observed previously for the +19 enhancer in conjunction with the Scl promoter (Sanchez et al., 1999). Of note, histological analysis demonstrated that LacZ expressing cells included fetal liver megakaryocytes (Figure S5C). These results demonstrate that a regulatory element previously thought to simply control expression of Scl can act in vivo to mediate expression from the Pdzk1ip1 promoter. However, the Scl +19 enhancer was previously shown to interact with both Scl as well as heterologous promoters (Sanchez et al., 1999). The experiments presented here therefore do not directly prove that the +19 enhancer normally mediates specific Pdzk1ip1 regulation in vivo. Our results are nevertheless suggestive of a model whereby two very different proteins are maintained in close linkage throughout vertebrate evolution because they share key regulatory elements to sustain their expression in hematopoietic cells where they both perform important functions. Similar coregulatory relationships may be common throughout the genome, and thus an important consideration to be taken into account when utilizing ChIP-Seq studies for the reconstruction of regulatory networks.

**DISCUSSION**

Detailed molecular studies have shown individual TFs to play critical roles at various stages of MK maturation. For example, a hypomorph mouse model of Gata1 displays reduced platelet numbers associated with deregulated MK proliferation and severely impaired cytoplasmic maturation (Shivdasani et al., 1997). The other TFs investigated in this study, GATA2, RUNX1, FLI1, and SCL, have also been previously shown to play important roles in MK differentiation (Growney et al., 2005; Hart et al., 2000; Huang et al., 2009b; Ichikawa et al., 2004; Mikola et al., 2003; Song et al., 1999; Spyropoulos et al., 2000). Of note, these four factors also represent key players in regulatory network circuits operating in HSPCs (Gottgens et al., 2002b; Landry et al., 2009; Pimanda et al., 2007) consistent with the previously suggested notion of significant overlap between transcriptional control mechanisms in MKs and HSPCs (Huang and Cantor, 2009).

The five-factor ChIP-Seq data set generated made it feasible for us to perform a global analysis of combinatorial transcriptional control in a human primary myeloid cell type. Previous studies, which only examined individual promoter fragments, had revealed transcriptional cooperativity in MKs between RUNX1 and GATA1 (Elagib et al., 2003; Xu et al., 2006) as well as between FLI1 and GATA1 (Huang et al., 2009a). The latter was somewhat surprising given the well characterized antagonism between GATA1 and ETS family TFs during erythroid differentiation. Our genome-wide data sets support frequent co-occupancy of GATA1 and FLI1 in MK cells with a total of 1335 regions bound simultaneously by both factors. However, the vast majority (1094) of these are bound by additional factors and binding of GATA1 and FLI1 without any of the other factors was in fact the most underrepresented occupancy pattern. These observations suggest that activatory interactions between GATA1 and FLI1 may at least in part be mediated through the assembly of larger multiprotein complexes. Of particular relevance may be the observation that ~700 regions are bound by GATA1 and FLI1 together with RUNX1. RUNX1 has been shown previously to interact at the protein level with both GATA1 and FLI1 (Huang et al., 2009a; Elagib et al., 2003). Moreover, RUNX1 expression is maintained in MKs whereas it is downregulated during erythroid differentiation (Elagib et al., 2003). Our combinatorial binding data are therefore consistent with a model where additional factors such as RUNX1 mediate transcriptional cooperation between GATA1 and FLI1 in MKs whereas antagonistic interactions may prevail in their absence as previously reported for the erythroid lineage.

Genes next to regions bound by all five factors were highly enriched for known regulators of MK differentiation and/or function. This observation prompted us to investigate the possibility that genes of unknown hematopoietic function with binding peaks for all five factors may also be enriched for the same functional categories. To provide biological insight, genome-scale hypothesis-generating screens such as ChIP-Seq experiments need to be coupled with meaningful assays for downstream functional validation. Here we took advantage of the zebrafish model because hematopoietic control mechanisms are highly conserved between zebrafish and human/mouse, yet only the zebrafish allows relatively high-throughput knockdown analysis in vivo in the context of a whole animal. Coupling the multifactor ChIP-Seq screen with zebrafish in vivo validation allowed us to identify eight regulators of thrombopoiesis and/or erythropoiesis. Of note, none of the MOs caused a lack of blood circulation and at the concentration used, with the exception of two (smox and max), MO knockdown did not affect wider aspects of morphology, underscoring the hematopoietic specificity of the uncovered phenotypes. Given that seven MOs affected both erythrocytes and thrombocytes, it is possible that at least some of those genes may operate at the level of immature progenitors or blood stem cells. Given the overlap of key transcriptional regulators in MKs and HSCs, potential functions in blood stem cells might perhaps not be too surprising but will require further fine dissection of knockdown phenotypes.

Recent ChIP-Seq studies of individual transcription factors in two different hematopoietic lineages suggested that binding patterns are largely lineage-specific (Heinz et al., 2010) with
shared peaks in one study of Scl being as low as 6% (Palli et al., 2011). Comparison of the megakaryocyte data generated here with a recently published hematopoietic progenitor data set (Wilson et al., 2010a) confirmed the predominance of lineage-specific binding patterns, and in addition demonstrated that regions bound by multiple factors are also largely lineage-specific. This suggests that additional lineage-specific transcription factors may play a part in controlling cell-type specific accessibility of regulatory regions through interactions with chromatin modifying enzymes. The likely relevance of additional MK-specific transcription factors is further emphasized by our observation that the five factors studied here may only account for 30% of MK-specific expression. Additional important players within MK transcriptional programs are likely to include NF-E2, MEIS1, and E2A (Shivdasani, 1996; Hisa et al., 2004; Semerad et al., 2009). Our demonstration that PDZK1IP1 shares transcriptional regulatory elements with the blood stem cell regulator SCL has implications reaching beyond a better understanding of this particular gene locus. The notion that a given regulatory region can control multiple genes is well established, but past experimental analysis has largely focused on clusters of related genes, such as the β-globin locus (Tohuis et al., 2002) or tandem arrays of interleukin genes (Loots et al., 2000). Coregulation within these gene loci is likely to have arisen in parallel with local gene duplication resulting in coordinated control of evolutionary and functionally related genes. By contrast, SCL and PDZK1IP1 encode unrelated proteins and it is likely that their original juxtaposition within vertebrate genomes was accidental. Our identification of PDZK1IP1 as a hematopoietic regulator together with the demonstration that SCL and PDZK1IP1 share transcriptional enhancer elements provides a rationale for the tight linkage between these two genes throughout vertebrate evolution. Moreover, our data illustrate the potential pitfalls of mapping transcription factor binding events to a single target gene when reconstructing regulatory networks. The +19 enhancer is approximately equidistant to the SCL and PDZK1IP1 promoters and evidently can control both. Transgenic in vivo analysis as performed here will be too time consuming and costly for global mapping of regulatory interactions between distal enhancers and the promoters of neighboring genes. However, further reductions in DNA sequencing costs may mean that chromatin-capture based methods providing a genome-wide view of promoter/enhancer interactions (Fullwood et al., 2009) will eventually perform this integral part of regulatory network reconstruction.

Previous multi-TF ChIP-Seq studies have revealed layers of information that can only be obtained from integrated analysis of multiple factors. For example, computational analysis of a 12-factor ChIP-Seq data set from mouse ESCs suggested that genome-scale analysis of combinatorial TF occupancy has the potential to predict absolute and differential gene expression (Ouyang et al., 2009). A five-factor ChIP-Seq study in an erythroid model cell line revealed that multi-TF complex binding often marks sites of long-range genomic interactions (Soler et al., 2010). Here we have shown that multifactor ChIP-Seq surveys coupled to high-throughput in vivo functional screening provide a powerful strategy toward isolating key regulators of cellular phenotypes. Future detailed functional analyses of the eight hematopoietic regulators identified here, has the potential to integrate new regulatory pathways into an emerging framework of blood development.

**EXPERIMENTAL PROCEDURES**

**Megakaryocyte Culture**

Cord blood was obtained after informed consent under a protocol approved by the National Research Ethics Service. CD34-positive cells (>98%) isolated by magnetic cell sorting (Miltenyi Biotec) were seeded at 1 x 10^5 cells/ml in Cellgro SCGM medium (CellGenix) with 100 ng/ml human TPO (Cellgenix) and 10 ng/ml IL-1 (Miltenyi Biotec) and incubated for 10 days. Flow cytometry was performed on a CyAn ADP 9 color (Beckman Coulter) as described (Macaulay et al., 2007) using the following antibodies: CD11cPECy5 or V450 (clone B-ly6; Becton Dickinson [BD]), CD14PE (clone M5E2; BD), CD15APC (clone HI98; BD) or V450 (clone MMA; BD), CD34PE (clone 581; Beckman Coulter), CD41APC (clone HI8; BD), CD24a (clone ALMA.16; BD), CD66f (clone B6.2; BD), and IgGAPC (clone MOPC-21; BD).

**Chromatin Immunoprecipitation**

ChIP assays were performed as previously described (Forsberg et al., 2000) with 9.4–12.6 x 10^5 cells and anti-GATA1 (ab11963, Abcam), anti-GATA2 (clone H-116, Santa Cruz), anti-RUNX1 (ab23980, Abcam), anti-FLI1 (ab15289, Abcam), anti-TALI antibody (clone C-21, Santa Cruz) and nonspecific Rabbit IgG (ab11100, Sigma Aldrich). Samples were sequenced using the Illumina Gil Genome Analyzer. Sequence data have been submitted to http://www.ncbi.nlm.nih.gov/geo (GEO record GSE24674).

**Zebrafish Knockdown**

General maintenance, collection, and staging were carried out according to the Zebrafish Book (Westerfield, 1994). Antisense MOs (Gene Tools) were designed complementary to the 5' sequence near the start of translation (max and sifu), or at splice junctions (ncor2, march2, smox, nfac1, pttg1lp, emilin1, and pdzk1ip1f). An aliquot of 0.8 nl morpholino-containing solution was injected in zebrafish embryos at the one- to two-cell stage. For march2 and pdzk1ip1, a MO concentration of 3 μg/μl and for ncor2, smox, nfac1, pttg1lp, max, emilin1, and sifu a MO concentration of 6 μg/μl was used. Efficiency of splice-site MOs was determined by RT-PCR (Table S7). Total RNA was isolated from control and splice MO injected embryos using the RNeasy Mini Kit (Qiagen) and cDNA synthesized using SuperScript III (Invitrogen). Staining of hemoglobin by o-dianisidine was performed as described (Macaulay et al., 2007) using the following antibodies: CD11cPE-Cy5 or V450 (clone HI98; BD) or V450 (clone MMA; BD), CD34PE (clone 581; Beckman Coulter), CD41APC (clone HI8; BD), CD24a (clone ALMA.16; BD), CD66f (clone B6.2; BD), and IgGAPC (clone MOPC-21; BD).

**ChIP-Seq Analysis**

Three peak finding programs (Peakseek [Rozowsky et al., 2009], Findpeaks [Fejes et al., 2008] and model-based analysis of ChIP-Seq [MACS] [Zhang et al., 2008]) were used, based on previous observations that there is no single algorithm of choice when calling peak regions for different TFs (Laajala et al., 2009). De novo motif discovery was performed using MEME (Bailey and Elkan, 1994) or bioprospector (Liu et al., 2001) and motifs were compared with the JASPAR_CORE database (Bryne et al., 2008). Matches to consensus sequences were determined as described using TFBSSearch (Chapman et al., 2004). Peaks in promoters and introns were allocated to that gene and the remainder of peaks to the nearest 3′ and 5′ genes in a 100 kb region. Intersect of genes lists were generated using Galaxy (Goecks et al., 2010), gene ontology terms were analyzed using GO Term Mapper (Lewis-Sigler Institute for Integrative Genomics at Princeton University), and gene set enrichment analysis was performed using the GSEA software (Subramanian et al., 2005).

**Pdzk1ip1 Knockdown**

To generate Pdzk1ip1 KI ESCs a targeting vector was generated by bacterial recombineering (Liu et al., 2003) where 131bp of exon 1 of Pdzk1ip1 (containing the ATG site) was substituted by a LacZ reporter gene and a LoxP-PGK-Neo-LoxP cassette. Targeting was determined by Southern blot using 5′ and 3′ probes outside the targeting vector. Targeted cells were transiently transfected with PGK-Cre for deletion of the Neo cassette (Figure S5). Pdzk1ip1
Identification of Hematopoietic Regulators

Developmental Cell

KI ES were differentiated into embryoid bodies as described (Keller et al., 1993) and stained with X-gal as described (Smith et al., 2008). For sorting, embryoid bodies were disrupted at day 6 of differentiation and stained with Fluorescein d(II)-D-galactopyranoside (FDG) (Sanchez et al., 1999). Cells were plated in methocult (Stem Cell Technologies) with appropriate cytokines (Peprotech, R&D) and scored after 7 days.

**Transgenic Mice and In Situ Hybridization**

Pdzk1ip1-P/Pr-Lac and +19/Pdzk1ip1-P/Pr-Lac transgenic constructs were generated by inserting a 4.5 kb fragment containing the Pdzk1ip1 promoter and a 640 bp fragment containing the +19 enhancer into the pGLo vector. Methods for transgenic mice generation and in situ hybridization are described elsewhere (Wilson et al., 2010b).

**ACCESSION NUMBERS**

Sequence data have been submitted to the NCBI Gene Expression Omnibus database (accession number GSE24674).

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Supplemental Experimental Procedures, Supplemental References, five figures, and seven tables and can be found with this article online at doi:10.1016/j.devcel.2011.04.008.

**ACKNOWLEDGMENTS**

We thank S. Charnock-Jones and staff at the Rosie Hospital for their help obtaining cord blood samples, G. Kiddle for help with sequencing, and A. Rendon for help with mapping ChiP-Seq reads. M.R.T. was supported by the Netherlands Organisation for Scientific Research (NWO; 2008/05927/ALW) and is currently a Marie Curie Intra-European Fellow (237296). A.C. and D.L.S. are supported by the Wellcome Trust (grants 082597/Z/07/Z, 077037/Z/05/Z, 077047/Z/05/Z, W.H.O. and P.A.S. are funded by the National Institute for Health Research/NHS Blood and Transplant (RP-PG-0310-1002), R.F., A.F., and A.R.G. are supported by the Wellcome Trust and K.O. and S.H.O. by the Kay Kendall Leukaemia Fund. Work in the Gottgens lab is supported by Leukaemia and Lymphoma Research, the Leukaemia and Lymphoma Society, the Medical Research Council, and the National Institute for Health Research Cambridge Biomedical Research Centre.

Received: October 13, 2010
Revised: February 28, 2011
Accepted: April 20, 2011
Published: May 16, 2011

**REFERENCES**


The genome-wide dynamics of the binding of Ldb1 complexes during erythroid differentiation. Genes Dev. 24, 277–289.


